Teva Hit With Patent Suit Over Pharmacosmos’ Pre-Chemo Drug

Teva Pharmaceutical Industries Ltd.’s proposed copy of Pharmacosmos Holdings A/S’ Cosela infringes two patents for the intravenous infusion used to prevent bone marrow suppression caused by chemotherapy, a federal lawsuit said.

Denmark-based Pharmacosmos alleges Teva’s generic version infringes US patent Nos. 11,529,352 and 12,168,666, according to a complaint filed Thursday in the US District Court for the District of New Jersey. It seeks an order blocking Teva’s copies until the patents have expired and damages if copies are made before then, the suit said.

• The ’666 patent—which covers specific forms of, and methods for making, trilaciclib, Cosela’s active ingredient—expires ...